Lantern Pharma announces multiple presentations at AACR 2019
Lantern Pharma announces multiple presentations at AACR 2019 highlighting
advancements of its precision oncology pipeline of therapeutics using their AI-based
platform, RADR™,to identify gene signatures that predict potential response of
patient’s tumor to a drug
NEW YORK, March 29, 2019 — Lantern Pharma, a clinical stage oncology biotech leveraging A.I.
and genomics, announces today that it will be presenting three abstracts at the upcoming
American Association for Cancer Research (AACR) Annual Meeting in Atlanta. Lantern Pharma
in-licenses and develops therapies using genomic data, machine learning and computational
biology modeling to identify the patient groups most likely to respond to the therapy, and to clarify
the potential underlying mechanism(s) of action. Lantern Pharma is developing a pipeline of
oncology therapeutics, two that are in clinical stages and one that is preclinical, that are being
advanced using Lantern’s AI platform, RADR™ (Response Algorithm for Drug Positioning and
Rescue) for indications in prostate cancer, ovarian cancer and non-small cell lung cancer. Lantern
leverages RADR™ in its precision oncology drug development approach, which uses genomics,
machine learning and proprietary in-vivo data to rescue, revitalize and develop cancer therapies
for patients with high and often unmet clinical needs.
RADR™ is being actively developed by Lantern and leverages over 25 million genomic data points
across 120 real world drug-tumor interactions, and Lantern is aggressively expanding the platform
with additional real-world data points, tumor specific data sets, proprietary in-vivo experimental
data, and additional validated drug-tumor models. Posters based on the abstracts at AACR will
highlight the capability of RADR™ in identifying gene signatures related to favorable response to
cancer therapies, and showcase some of the key methods being used by Lantern in the
development of patient stratification algorithms and neural network based approaches for
machine learning.
Each of the three posters provides a glimpse into Lantern Pharma’s dedication to paving a path for
the use of AI in precision oncology, where millions of data points have been gathered from
real-world clinical data and narrowed down to biologically and statistically meaningful gene
signatures. These genomic signatures can then be used to select patients for clinical trials and
ensure the highest likelihood of a meaningful clinical response to Lantern’s portfolio of drug
candidates.
The AACR annual meeting will take place March 29-April 3, 2019, in Atlanta, Georgia, at the
Georgia World Congress Center.
POSTER PRESENTATION DETAILS:
Poster One:
“Establishment of a drug-tumor interaction database using Lantern Pharma’s Response Algorithm
for Drug Positioning and Rescue”, presented by Umesh Kathad, M.S.
Sunday, March 31, 2019. 1-5 pm
Hall B, Georgia World Congress Center
Bioinformatics and Systems Biology
Section 30: Convergence Science for Therapeutics and Precision Medicine
Board 5: Establishment of a drug-tumor interaction database using Lantern Pharma’s
Response Algorithm for Drug Positioning and Rescue
Poster Two:
“Clinical validation of Lantern Pharma’s Response Algorithm for Drug Positioning and Rescue”,
presented by Yuvanesh Vedaraju, M.S.
Tuesday, April 2, 2019, 8am- 12pm
Hall B, Georgia World Congress Center
Clinical Research
Section 21: Tumor Markers to Assess the Biology and Clinical Course of Cancer 1
Board 7: Clinical validation of Lantern Pharma’s Response Algorithm for Drug
Positioning and Rescue
Poster Three:
“Predicting sensitivity to Lantern Pharma’s pipeline drug candidate LP-184 using the Response
Algorithm for Drug Positioning and Rescue”, presented by Aditya Kulkarni, Ph.D.
Wednesday, April 3, 2019, 8-10am
Hall A, Georgia World Congress Center
Experimental and Molecular Therapeutics
Section 13: Novel Antitumor Agents 3
Board 3: Predicting sensitivity to Lantern Pharma’s pipeline drug candidate LP-184 using
the Response Algorithm for Drug Positioning and Rescue
Full abstracts for the poster presentations can be found at the AACR annual meeting website,
www.aacr.org. They will also be available after the presentations at the Company’s website –
www.lanternpharma.com.
About Lantern Pharma
Lantern Pharma is a clinical stage biopharmaceutical company innovating the repurposing,
revitalization and development of precision therapeutics in oncology. We leverage advances in
machine learning, genomics and artificial intelligence by using a proprietary AI platform to
discover biomarker signatures that help identify patients more likely to respond to our pipeline of
cancer therapeutics. Lantern’s focus is to improve the outcome for patients by leveraging our
technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of
three drugs, two in clinical stages and one in preclinical, focuses on cancers that have unique and
unmet clinical needs with a clearly defined patient population. We believe that the use of machine
learning, genomics and computational methods can help accelerate the revitalization, refocusing
and development of small molecule-based therapies. These drugs can be targeted to patients
whose genomic profile identifies them as having the highest probability of benefiting from the
drug, thereby delivering best-in-class outcomes. Our team seeks out experienced industry
partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver
cancer therapies to patients as quickly and efficiently as possible. For more information, please
visit the company’s website at www.lanternpharma.com or view company updates
@lanternpharma.